Smith Graham & Co Investment Advisors Lp decreased Guess Inc (GES) stake by 27.48% reported in 2017Q3 SEC filing. Smith Graham & Co Investment Advisors Lp sold 106,180 shares as Guess Inc (GES)’s stock declined 24.42%. The Smith Graham & Co Investment Advisors Lp holds 280,204 shares with $4.77M value, down from 386,384 last quarter. Guess Inc now has $1.26 billion valuation. The stock increased 2.82% or $0.42 during the last trading session, reaching $15.33. About 1.14 million shares traded. Guess', Inc. (NYSE:GES) has declined 38.50% since March 14, 2017 and is downtrending. It has underperformed by 55.20% the S&P500.
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $32.54 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.
Knoll Capital Management Lp holds 0.64% of its portfolio in Evoke Pharma, Inc. for 225,000 shares. Sphera Funds Management Ltd. owns 571,022 shares or 0.27% of their US portfolio. Moreover, Family Management Corp has 0.02% invested in the company for 10,425 shares. The Michigan-based State Treasurer State Of Michigan has invested 0.01% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 10,000 shares.
Analysts await Evoke Pharma, Inc. (NASDAQ:EVOK) to report earnings on May, 21. They expect $-0.17 earnings per share, down 21.43% or $0.03 from last year’s $-0.14 per share. After $-0.22 actual earnings per share reported by Evoke Pharma, Inc. for the previous quarter, Wall Street now forecasts -22.73% EPS growth.
Ratings analysis reveals 50% of Evoke Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Evoke Pharma, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $2.5 while the high is $8.0. The stock’s average target of $5.25 is 150.00% above today’s ($2.1) share price. EVOK was included in 2 notes of analysts from December 23, 2016. Rodman & Renshaw maintained the stock with “Neutral” rating in Friday, December 23 report. The stock of Evoke Pharma, Inc. (NASDAQ:EVOK) has “Buy” rating given on Monday, January 30 by Laidlaw.
The stock increased 5.00% or $0.1 during the last trading session, reaching $2.1. About 137,891 shares traded or 38.25% up from the average. Evoke Pharma, Inc. (EVOK) has declined 51.99% since March 14, 2017 and is downtrending. It has underperformed by 68.69% the S&P500.
Analysts await Guess', Inc. (NYSE:GES) to report earnings on March, 21 after the close. They expect $0.53 earnings per share, up 29.27% or $0.12 from last year’s $0.41 per share. GES’s profit will be $43.60M for 7.23 P/E if the $0.53 EPS becomes a reality. After $0.12 actual earnings per share reported by Guess', Inc. for the previous quarter, Wall Street now forecasts 341.67% EPS growth.
Among 12 analysts covering Guess? (NYSE:GES), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Guess? had 43 analyst reports since August 15, 2015 according to SRatingsIntel. As per Tuesday, January 9, the company rating was maintained by FBR Capital. As per Friday, May 5, the company rating was maintained by Jefferies. The stock of Guess', Inc. (NYSE:GES) has “Hold” rating given on Wednesday, August 16 by Jefferies. The firm earned “Market Perform” rating on Thursday, March 16 by Telsey Advisory Group. FBR Capital maintained the stock with “Buy” rating in Friday, July 21 report. As per Friday, March 10, the company rating was downgraded by B. Riley & Co. The firm has “Buy” rating by Mizuho given on Thursday, August 27. The rating was maintained by Mizuho on Thursday, May 26 with “Neutral”. The firm has “Hold” rating by Jefferies given on Thursday, September 28. Mizuho maintained the shares of GES in report on Thursday, December 1 with “Neutral” rating.